Last reviewed · How we verify
Ulthera System Treatment
At a glance
| Generic name | Ulthera System Treatment |
|---|---|
| Also known as | Ultherapy™ |
| Sponsor | Ulthera, Inc |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety and Effectiveness Evaluation of the High-intensity Focused Ultrasound Device for Lifting Lax Submental and Neck Tissue (NA)
- Evaluation of the Effectiveness and Safety of the Ulthera® DeepSEE® System for Treating Skin Laxity in the Lower Face and Submentum (NA)
- Superficial MFU-V and Diluted Calcium Hydroxyapatite for the Improvement of Lower Face Skin Quality and Wrinkles (NA)
- Simulines Non-Inferiority Pivotal Study (NA)
- Open-label, Prospective Evaluation of the Ulthera® System for Lifting Submental (Under the Chin) and Neck Tissue in Chinese Patients (NA)
- Evaluation of the Ulthera System for Treating Axillary Hyperhidrosis (NA)
- Evaluation of the Ulthera® System and Efficacy Correlation to Morphological Differences (NA)
- Ultherapy® for Treating the Face and Neck Using Standard Versus Simulines Transducers (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ulthera System Treatment CI brief — competitive landscape report
- Ulthera System Treatment updates RSS · CI watch RSS
- Ulthera, Inc portfolio CI